HC Wainwright Issues Pessimistic Outlook for ACHV Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Investment analysts at HC Wainwright lowered their FY2026 earnings per share (EPS) estimates for Achieve Life Sciences in a research report issued to clients and investors on Monday, January 26th. HC Wainwright analyst B. Folkes now anticipates that the biopharmaceutical company will earn ($1.35) per share for the year, down from their prior estimate of ($1.30). The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Achieve Life Sciences’ FY2027 earnings at ($0.54) EPS, FY2028 earnings at $0.47 EPS and FY2029 earnings at $1.20 EPS.

A number of other brokerages also recently issued reports on ACHV. Raymond James Financial reissued a “strong-buy” rating on shares of Achieve Life Sciences in a research report on Monday, November 24th. Citigroup began coverage on Achieve Life Sciences in a research report on Tuesday, November 25th. They set an “outperform” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Achieve Life Sciences in a research note on Monday, December 29th. Finally, Citizens Jmp initiated coverage on shares of Achieve Life Sciences in a report on Tuesday, November 25th. They set a “market outperform” rating and a $19.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Achieve Life Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $15.50.

Achieve Life Sciences Trading Down 9.4%

Shares of ACHV stock opened at $4.61 on Wednesday. The company has a current ratio of 5.14, a quick ratio of 5.14 and a debt-to-equity ratio of 0.26. The company’s 50-day moving average price is $4.85 and its 200-day moving average price is $3.88. Achieve Life Sciences has a twelve month low of $1.84 and a twelve month high of $6.03. The stock has a market cap of $245.39 million, a price-to-earnings ratio of -3.34 and a beta of 1.71.

Achieve Life Sciences (NASDAQ:ACHV) last announced its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04).

Institutional Trading of Achieve Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACHV. AQR Capital Management LLC acquired a new position in Achieve Life Sciences in the first quarter valued at $32,000. Manchester Financial Inc. grew its position in Achieve Life Sciences by 90.8% in the second quarter. Manchester Financial Inc. now owns 46,224 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 22,000 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Achieve Life Sciences during the second quarter worth about $263,000. Simplify Asset Management Inc. grew its position in shares of Achieve Life Sciences by 443.7% during the second quarter. Simplify Asset Management Inc. now owns 1,184,512 shares of the biopharmaceutical company’s stock worth $2,677,000 after buying an additional 966,667 shares in the last quarter. Finally, Highbridge Capital Management LLC bought a new stake in shares of Achieve Life Sciences in the 2nd quarter worth about $300,000. Hedge funds and other institutional investors own 33.52% of the company’s stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.